Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig and ARX517 in Metastatic Castration-Resistant Prostate Cancer
NCT07082920Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of pasritamig and ARX517 in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events and Dose-Limiting Toxicity. Started Jul 2025; status: recruiting.
02
Drugs
pasritamigARX517
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07082920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082920.